[ad_1]
For the first time, the World Health Organization has recommended providing a group of drugs to prevent acute symptoms of “Covid-19” disease in patients at risk.
The World Health Organization has referred to studies indicating that a combination of kazerifimab and imdivimab, developed by the American company “Regeneron” in partnership with the Swiss company “Roche”, could improve the chances of survival of patients, according to the German press agency.
WHO now recommends kazerifimab and imdivimab for patients with pre-existing coronaviruses who may have severe symptoms of COVID-19 and facial treatment in intensive care units.
The World Health Organization published its new recommendations in the British Medical Journal.
The World Health Organization said in a statement that the patients most at risk of hospitalization and those who have not developed natural antibodies against “Covid-19” are the two groups of patients who benefit from the more than one drug treatment.
The organization urged manufacturers and governments to tackle the high price and limited production of the “Regeneron” antibody mixture, and said negotiations were underway with “Roche” over lower prices, a potential donation and an equitable distribution in the world.
[ad_2]
Source link
